Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
Abstract Objective We investigated the efficacy and safety of carfilzomib‐containing induction before salvage high‐dose melphalan with autologous stem‐cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. Methods This randomised, open‐label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re‐induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv carfilzomib 27 → 56 mg/sqm and p.o. dexamethasone 20 mg every second week. The study enrolled 200 patients of which 168 were randomised to either maintenance with carfilzomib and dexamethasone (n = 82) or observation (n = 86). Results Median time to progression (TTP) after randomisation was 25.1 months (22.5‐NR) in the carfilzomib‐dexamethasone maintenance group and 16.7 months (14.4–21.8) in the control group (HR 0.46, 95% CI 0.30–0.71; P = .0004). The most common adverse events during maintenance were thrombocytopenia, anaemia, hypertension, dyspnoea and bacterial infections. Conclusion In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well‐tolerated with manageable toxicity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
European Journal of Haematology - 108(2022), 1, Seite 34-44 |
| Beteiligte Personen: |
Gregersen, Henrik [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
|---|
| doi: |
10.1111/ejh.13709 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004986741 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004986741 | ||
| 003 | DE-627 | ||
| 005 | 20230307142749.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/ejh.13709 |2 doi | |
| 028 | 5 | 2 | |a EJH_EJH13709.xml |
| 035 | |a (DE-627)WLY004986741 | ||
| 035 | |a (WILEY)EJH13709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Gregersen, Henrik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma |b A randomised phase 2 trial by the Nordic Myeloma Study Group |
| 264 | 1 | |c 2022 | |
| 300 | |a 0 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd | ||
| 520 | |a Abstract Objective We investigated the efficacy and safety of carfilzomib‐containing induction before salvage high‐dose melphalan with autologous stem‐cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. Methods This randomised, open‐label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re‐induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv carfilzomib 27 → 56 mg/sqm and p.o. dexamethasone 20 mg every second week. The study enrolled 200 patients of which 168 were randomised to either maintenance with carfilzomib and dexamethasone (n = 82) or observation (n = 86). Results Median time to progression (TTP) after randomisation was 25.1 months (22.5‐NR) in the carfilzomib‐dexamethasone maintenance group and 16.7 months (14.4–21.8) in the control group (HR 0.46, 95% CI 0.30–0.71; P = .0004). The most common adverse events during maintenance were thrombocytopenia, anaemia, hypertension, dyspnoea and bacterial infections. Conclusion In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well‐tolerated with manageable toxicity. | ||
| 700 | 1 | |a Peceliunas, Valdas |4 aut | |
| 700 | 1 | |a Remes, Kari |4 aut | |
| 700 | 1 | |a Schjesvold, Fredrik |4 aut | |
| 700 | 1 | |a Abildgaard, Niels |4 aut | |
| 700 | 1 | |a Nahi, Hareth |4 aut | |
| 700 | 1 | |a Andersen, Niels Frost |4 aut | |
| 700 | 1 | |a Vangsted, Annette Juul |4 aut | |
| 700 | 1 | |a Klausen, Tobias Wirenfeldt |4 aut | |
| 700 | 1 | |a Helleberg, Carsten |4 aut | |
| 700 | 1 | |a Carlson, Kristina |4 aut | |
| 700 | 1 | |a Frølund, Ulf Christian |4 aut | |
| 700 | 1 | |a Axelsson, Per |4 aut | |
| 700 | 1 | |a Stromberg, Olga |4 aut | |
| 700 | 1 | |a Blimark, Cecilie Hveding |4 aut | |
| 700 | 1 | |a Crafoord, Jacob |4 aut | |
| 700 | 1 | |a Tsykunova, Galina |4 aut | |
| 700 | 1 | |a Eshoj, Henrik Rode |4 aut | |
| 700 | 1 | |a Waage, Anders |4 aut | |
| 700 | 1 | |a Hansson, Markus |4 aut | |
| 700 | 1 | |a Gulbrandsen, Nina |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European Journal of Haematology |g 108(2022), 1, Seite 34-44 |w (DE-627)WLY004983017 |x 16000609 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2022 |g number:1 |g pages:34-44 |g extent:0 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.86 |q ASE |
| 951 | |a AR | ||
| 952 | |d 108 |j 2022 |e 1 |h 34-44 |g 0 | ||